Analyzing Anixa Biosciences (NASDAQ:ANIX) & PainReform (NASDAQ:PRFX)

Anixa Biosciences (NASDAQ:ANIX) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Volatility and Risk

Anixa Biosciences has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, PainReform has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Valuation & Earnings

This table compares Anixa Biosciences and PainReform’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210,000.00	481.54	-$9.81 million	($0.34)	-9.32
PainReform	N/A	N/A	-$9.34 million	N/A	N/A

PainReform has lower revenue, but higher earnings than Anixa Biosciences.

Profitability

This table compares Anixa Biosciences and PainReform’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-44.09%	-40.90%
PainReform	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings for Anixa Biosciences and PainReform, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	0	0	1	0	3.00
PainReform	0	0	0	0	N/A

Anixa Biosciences presently has a consensus target price of $12.00, indicating a potential upside of 278.55%. Given Anixa Biosciences’ higher possible upside, research analysts plainly believe Anixa Biosciences is more favorable than PainReform.

Insider & Institutional Ownership

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 22.6% of Anixa Biosciences shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

PainReform beats Anixa Biosciences on 5 of the 9 factors compared between the two stocks.

About Anixa Biosciences

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. The company engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. It is currently conducting Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. The company was incorporated in 2007 and is based in Tel Aviv, Israel.